Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Paolo Peterlongo
  • Jenny Chang-Claude
  • Kirsten B Moysich
  • Anja Rudolph
  • Rita K Schmutzler
  • Jacques Simard
  • Penny Soucy
  • Rosalind A Eeles
  • Douglas F Easton
  • Ute Hamann
  • Stefan Wilkening
  • Bowang Chen
  • Matti A Rookus
  • Marjanka K Schmidt
  • Frederieke H van der Baan
  • Amanda B Spurdle
  • Logan C Walker
  • Felicity Lose
  • Ana-Teresa Maia
  • Marco Montagna
  • Laura Matricardi
  • Jan Lubinski
  • Anna Jakubowska
  • Encarna B Gómez Garcia
  • Olufunmilayo I Olopade
  • Robert L Nussbaum
  • Katherine L Nathanson
  • Susan M Domchek
  • Timothy R Rebbeck
  • Banu K Arun
  • Beth Y Karlan
  • Sandra Orsulic
  • Jenny Lester
  • Wendy K Chung
  • Alex Miron
  • Melissa C Southey
  • David E Goldgar
  • Saundra S Buys
  • Ramunas Janavicius
  • Cecilia M Dorfling
  • Elizabeth J van Rensburg
  • Yuan Chun Ding
  • Susan L Neuhausen
  • Thomas V O Hansen
  • Anne-Marie Gerdes
  • Bent Ejlertsen
  • Lars Jønson
  • Ana Osorio
  • Cristina Martínez-Bouzas
  • Javier Benitez
  • EMBRACE
Vis graf over relationer

BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes.

METHODS: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach.

RESULTS: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments.

CONCLUSION: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.

IMPACT: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies.

OriginalsprogEngelsk
TidsskriftCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Vol/bind24
Udgave nummer1
Sider (fra-til)308-16
Antal sider9
ISSN1055-9965
DOI
StatusUdgivet - jan. 2015

ID: 45089351